Phase 2 Lymphoma Trial, Recruiting NCT07272499 Sponsor: Ruijin Hospital Condition: Lymphoma
Back to Lymphoma

Phase 2 Lymphoma Trial, Recruiting

NCT07272499
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with mantle cell lymphoma (a type of blood cancer) confirmed through laboratory testing, and who have not yet received any treatment for it.
  • People who are older than 14 years of age; both males and females are eligible.
  • People whose cancer is classified as stage II, III, or IV (using a standard staging system called Ann Arbor); for stage II, the treating doctor must consider systemic (whole-body) treatment to be necessary.
  • People who have at least one tumour or affected area that can be measured on scans.
  • People who have at least one of the following higher-risk features: a MIPI score of 6–11 (a scoring system used by doctors to assess disease risk), a Ki67 value above 30% (a measure of how quickly cancer cells are growing), a specific gene change or protein result related to TP53/p53, or a particular aggressive form of the disease called blastic or pleomorphic variant (confirm with trial site).
  • People whose blood test results meet specific requirements for white blood cells, neutrophils (infection-fighting cells), haemoglobin (a measure of red blood cells), and platelets, as well as normal ranges for liver and kidney function tests.
  • People whose doctor estimates they are expected to live for more than 12 weeks from the time of screening.
  • People who are willing and able to attend all required visits and follow all study procedures.

Who may not be able to join:

  • People who have previously been treated with a type of medication called a BTK inhibitor.
  • People who have serious existing health complications or severe active infections.
  • People with heart or blood vessel disease, blood clotting problems, connective tissue diseases, or other serious infections that are not under control.
  • People who currently have an active infection (bacterial, fungal, or viral) that requires treatment with medication taken throughout the body (such as oral or intravenous antibiotics or antivirals).
  • People who are living with HIV.
  • People who have a mental health condition, or who the doctor believes may not be able to fully follow the study requirements.
  • People who the investigator considers unsuitable for the trial for any other reason.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 8 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +862164370045

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Registry
ClinicalTrials.gov
Start date
10 September 2025
Est. completion
10 September 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Complete response rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov